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Scientific object
The epidemic diffusion of diabetes mellitus has raised
serious concerns about the deleterious effects of its
complications. Diabetic retinopathy (DR) is a severe pro-
gressive ocular pathology and the leading cause of blind-
ness in adults. There is a significant limitation in
specific biomarkers for DR, thus, implying that DR diag-
nosis occur when vision is already compromised. Poor
glycemic control, with elevated hemoglobin A1c
(HbA1c), and hypertension are recognized risk factors,
however the implication of inflammatory processes in
DR pathogenesis has prompt interest in the identifica-
tion of biomarkers of disease within the immune system.
Technical approach/methods
By using flow cytometry and multiplex ELISA assays, we
have analyzed a large number of inflammatory cytokines
and determinants of innate immunity in serum of dia-
betic patients at different stages of DR. In addition, we
have analyzed and compared the expression pattern of
these factors in post-mortem retinas and vitreous of dia-
betic donors.
Results/interpretation
A quite large number of pro-inflammatory factors were
up-regulated in the serum of diabetic patients, but only
a restricted number of them were correlated with clini-
cally overt DR. We have focused our attention on three
factors and pursued more studies on their contribution
to DR induction and progression. The results of these
studies have determined that toll-like receptor 4 (TLR4),
interleukin 17 (IL-17) and uricemia are all potentially
involved in promoting auto-inflammatory activity both
systemically and in retina of diabetic patients. In parti-
cular, while elevation of TLR4 expression and activity
along with increased uric acid levels were predictive of
DR induction in all stages, increased levels of IL-17 was
found in patients affected by most severe stages of DR
such as macular edema and proliferative diabetic retino-
pathy. These data support the hypothesis that monitor-
ing of pro-inflammatory factors in serum of diabetic
patients held predictive value for DR. In addition, our
results, suggest that a definite set of factors are directly
associated with different stages of retinopathy in diabetic
patients.
Authors’ details
1Department of Pharmacology and Toxicology –Georgia Regents University-
Augusta, GA 30912 –USA. 2Department of Ophthalmology – Georgia
Regents University- Augusta, GA 30912- USA. 3Department of Oral Biology –
Georgia Regents University- Augusta, GA 30912- USA. 4Department of
Experimental Medicine and Pathology – University of Rome “La Sapienza” –
Rome, Italy. 5Department of Hematology and Oncology - Istituto Superiore
di Sanita’ - Rome, Italy. 6IRCCS Fondazione GB Bietti- Rome, Italy.
Published: 11 February 2014
doi:10.1186/1878-5085-5-S1-A79
Cite this article as: Lamoke et al.: Validation of biomarkers of diabetic
retinopathy for preventing and predictive medicine in diabetic
complications. EPMA Journal 2014 5(Suppl 1):A79.
* Correspondence: flamoke@gru.edu
1Department of Pharmacology and Toxicology –Georgia Regents University-
Augusta, GA 30912 –USA
Full list of author information is available at the end of the article
Lamoke et al. EPMA Journal 2014, 5(Suppl 1):A79
http://www.epmajournal.com/content/5/S1/A79
© 2014 Lamoke et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
